203 related articles for article (PubMed ID: 19709746)
21. LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL.
Prieto D; Seija N; Uriepero A; Souto-Padron T; Oliver C; Irigoin V; Guillermo C; Navarrete MA; Inés Landoni A; Dighiero G; Gabus R; Giordano M; Oppezzo P
Br J Haematol; 2018 Aug; 182(4):521-525. PubMed ID: 29953583
[TBL] [Abstract][Full Text] [Related]
22. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
[TBL] [Abstract][Full Text] [Related]
23. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
[TBL] [Abstract][Full Text] [Related]
24. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression.
Bilban M; Heintel D; Scharl T; Woelfel T; Auer MM; Porpaczy E; Kainz B; Kröber A; Carey VJ; Shehata M; Zielinski C; Pickl W; Stilgenbauer S; Gaiger A; Wagner O; Jäger U;
Leukemia; 2006 Jun; 20(6):1080-8. PubMed ID: 16617321
[TBL] [Abstract][Full Text] [Related]
25. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
26. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
[TBL] [Abstract][Full Text] [Related]
27. Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy.
Donisi PM; Di Lorenzo N; Riccardi M; Paparella A; Sarpellon C; Zupo S; Bertoldero G; Minotto C; Stracca-Pansa V
Diagn Mol Pathol; 2006 Dec; 15(4):206-15. PubMed ID: 17122648
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
29. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia.
Potter KN; Mockridge CI; Neville L; Wheatley I; Schenk M; Orchard J; Duncombe AS; Packham G; Stevenson FK
Clin Cancer Res; 2006 Mar; 12(6):1672-9. PubMed ID: 16551848
[TBL] [Abstract][Full Text] [Related]
30. GALNT11 as a new molecular marker in chronic lymphocytic leukemia.
Libisch MG; Casás M; Chiribao M; Moreno P; Cayota A; Osinaga E; Oppezzo P; Robello C
Gene; 2014 Jan; 533(1):270-9. PubMed ID: 24076351
[TBL] [Abstract][Full Text] [Related]
31. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
32. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments.
Cahill N; Bergh AC; Kanduri M; Göransson-Kultima H; Mansouri L; Isaksson A; Ryan F; Smedby KE; Juliusson G; Sundström C; Rosén A; Rosenquist R
Leukemia; 2013 Jan; 27(1):150-8. PubMed ID: 22922567
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes.
Porakishvili N; Kulikova N; Jewell AP; Youinou PY; Yong K; Nathwani A; Heelan B; Duke V; Hamblin TJ; Wallace P; Ely P; Clark EA; Lydyard PM
Br J Haematol; 2005 Nov; 131(3):313-9. PubMed ID: 16225650
[TBL] [Abstract][Full Text] [Related]
34. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.
Tobin G; Thunberg U; Laurell A; Karlsson K; Aleskog A; Willander K; Söderberg O; Merup M; Vilpo J; Hultdin M; Sundström C; Roos G; Rosenquist R
Haematologica; 2005 Apr; 90(4):465-9. PubMed ID: 15820941
[TBL] [Abstract][Full Text] [Related]
35. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
[TBL] [Abstract][Full Text] [Related]
36. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.
Scielzo C; Ghia P; Conti A; Bachi A; Guida G; Geuna M; Alessio M; Caligaris-Cappio F
J Clin Invest; 2005 Jun; 115(6):1644-50. PubMed ID: 15931393
[TBL] [Abstract][Full Text] [Related]
37. Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.
Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Exp Hematol; 2013 Jul; 41(7):615-26. PubMed ID: 23548418
[TBL] [Abstract][Full Text] [Related]
38. IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors.
Belessi CJ; Davi FB; Stamatopoulos KE; Degano M; Andreou TM; Moreno C; Merle-Béral H; Crespo M; Laoutaris NP; Montserrat E; Caligaris-Cappio F; Anagnostopoulos AZ; Ghia P
Eur J Immunol; 2006 Jul; 36(7):1963-74. PubMed ID: 16783849
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Ma W; Kantarjian H; O'Brien S; Jilani I; Zhang X; Estrov Z; Ferrajoli A; Keating M; Giles F; Albitar M
Cancer; 2008 Mar; 112(6):1306-12. PubMed ID: 18224667
[TBL] [Abstract][Full Text] [Related]
40. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
Dal-Bo M; Del Giudice I; Bomben R; Capello D; Bertoni F; Forconi F; Laurenti L; Rossi D; Zucchetto A; Pozzato G; Marasca R; Efremov DG; Guarini A; Del Poeta G; Foà R; Gaidano G; Gattei V
Br J Haematol; 2011 Apr; 153(1):3-14. PubMed ID: 21303354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
